SU1720650A1 - Antidote "alloxime" in poisoning with organophosphorous compounds - Google Patents
Antidote "alloxime" in poisoning with organophosphorous compounds Download PDFInfo
- Publication number
- SU1720650A1 SU1720650A1 SU762370952A SU2370952A SU1720650A1 SU 1720650 A1 SU1720650 A1 SU 1720650A1 SU 762370952 A SU762370952 A SU 762370952A SU 2370952 A SU2370952 A SU 2370952A SU 1720650 A1 SU1720650 A1 SU 1720650A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- poisoning
- antidote
- alloxime
- organophosphorous compounds
- allyl
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
В качестве антидота при отравлении фосфорорганическими соединени ми примен етс М-аллил-2-пиридинэльдоксим бромида.M-allyl-2-pyridine eldoxime bromide is used as an antidote for poisoning with organophosphorus compounds.
Description
Изобретение относитс к медицине, в частности к средствам дл лечени отравлений фосфорорганическими соединени ми (карбофос, хлорофос и др.).The invention relates to medicine, in particular to agents for the treatment of organophosphate poisoning (karbofos, chlorophos, etc.).
В качестве средств дл лечени интоксикаций фосфорорганическими соединени ми (ФОС) используют реактивы холинэстеразы, например дипироксим.Cholinesterase reagents, such as dipyroxime, are used as agents for treating intoxication with organophosphorus compounds (FOS).
Целью изобретени вл етс применение в качестве антидота дл лечени отравлений ФОС средства, проникающего через гематрэнцефалический барьер.The aim of the invention is the use as an antidote for the treatment of FOS poisoning by means of penetrating through the hematoencephalic barrier.
Поставленна цель достигаетс тем, что примен ют М-аллил-2-пиридинальдоксим бромида в качестве антидота при отравлении ФОС.This goal is achieved by using M-allyl-2-pyridinaldoxime bromide as an antidote for FOS poisoning.
М-аллил-2-пиридинальдоксим бромид представл ет собой синтезированное соединение , белое с сероватым оттенком, без запаха, легко растворим в воде, мало растворим в органических растворител х.M-allyl-2-pyridinaldoxime bromide is a synthesized compound, white with a grayish tint, odorless, easily soluble in water, little soluble in organic solvents.
В отличие от известных реактивов, в том числе и дипироксима, в структуру М-аллил- 2-пиридинальдоксим бромида включена непредельна (аллильна ) группировка у четвертичного атома азота, что создало услови дл увеличени способности препарата проникать через гематознцефзлический барьер.In contrast to the known reagents, including dipyroxime, the unsaturated (allyl) group at the quaternary nitrogen atom is included in the structure of M-allyl-2-pyridinaldoxime bromide, which created conditions for increasing the ability of the drug to penetrate through the hematological research barrier.
Препарат целесообразно примен ть в разовой дозе 75 мг через б ч, череду с атропином, .в течение 3 сут с последующим введением по показанию 75 мг два раза в сутки до восстановлени ХЭ и улучшени состо ни больного при интоксикации средней и т желой степени. При легкой степени интоксикации по 75 мг 1-2 раза в сутки в течение 2-3 дней.It is advisable to use the drug in a single dose of 75 mg every 6 hours, in succession with atropine, for 3 days, followed by administration as indicated 75 mg twice a day until CE is restored and the patient's condition improves with moderate and severe intoxication. With mild intoxication 75 mg 1-2 times a day for 2-3 days.
Пример. Вводили препарат Аллок- сим внутримышечно по 75 мгс интервалом между инъекци ми от 1. до 3 ч в течение первых суток интоксикации на фоне проведени больному интенсивной и поддерживающей атропинизации. При этом обнаруживали на электроэнцефалограмме биоэлектрическую активность мозга длительностью 20-30 мин и улучшение активности с по влением нормального альфа-ритма. При исследовании нервно-мышечной проводимости наблюдалось исчезновение и умень- шение миофибрил ции после каждого повторного введени препарата.Example. The drug Alloxim was administered intramuscularly at 75 mg with an interval between injections from 1. to 3 hours during the first day of intoxication while the patient was undergoing intensive and supporting atropinization. At the same time, on the electroencephalogram, the bioelectric activity of the brain was detected for 20–30 min and the activity improved with the appearance of a normal alpha rhythm. In the study of neuromuscular conductivity, disappearance and reduction of myofibrillation were observed after each repeated administration of the drug.
Аллоксим эффективен при т желых отравлени х ФОС,Alloxime is effective in severe FOS poisoning,
fefe
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU762370952A SU1720650A1 (en) | 1976-06-10 | 1976-06-10 | Antidote "alloxime" in poisoning with organophosphorous compounds |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU762370952A SU1720650A1 (en) | 1976-06-10 | 1976-06-10 | Antidote "alloxime" in poisoning with organophosphorous compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1720650A1 true SU1720650A1 (en) | 1992-03-23 |
Family
ID=20665080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU762370952A SU1720650A1 (en) | 1976-06-10 | 1976-06-10 | Antidote "alloxime" in poisoning with organophosphorous compounds |
Country Status (1)
| Country | Link |
|---|---|
| SU (1) | SU1720650A1 (en) |
-
1976
- 1976-06-10 SU SU762370952A patent/SU1720650A1/en active
Non-Patent Citations (1)
| Title |
|---|
| Авторское свидетельство СССР № 1094289,кл. А 61 К 33/42,1971.. * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lundy et al. | Ganglion blocking properties of some bispyridinium soman antagonists | |
| KR900701282A (en) | Treatment, prevention of ischemic diseases of the heart or brain | |
| RU2000102359A (en) | PHARMACEUTICAL COMPOSITION HAVING AN IMPROVED ANTI-CANCER ACTION AND / OR REDUCED SIDE EFFECTS CONTAINING ANTI-CANCER AGENT AND HYDROXAMIC DERIVATIVE DERIVATIVE | |
| Dembińska-Kieć et al. | Effect of prostacyclin on fibrinolytic activity in patients with arteriosclerosis obliterans | |
| US4820711A (en) | Method for treating actinic keratosis with cytotoxic agents | |
| RU95105973A (en) | Method of toxoplasmosis severity decrease, pharmaceutical composition, use of rifamycin derivatives for preparing the medicinal preparations for toxoplasmosis treatment | |
| AU549890B2 (en) | Para-substituted-3-phenoxy-1-alkoxycarbenyl-alkylamino- propanol-2 compounds | |
| SU1720650A1 (en) | Antidote "alloxime" in poisoning with organophosphorous compounds | |
| Vick et al. | Neurological and physiological responses of the primate to anthrax toxin | |
| FR2420344A1 (en) | NEW OXIME-ETHERS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION. | |
| Harstrick et al. | A phase I dose escalation trial of intravenous treosulfan in refractory cancer | |
| Chinushi et al. | Nicorandil suppresses a hump on the monophasic action potential and torsade de pointes in a patient with idiopathic long QT syndrome | |
| Berger et al. | Pharmacologic properties of a new tranquillizing agent, 2-methyl-2-propyltrimethylene butylcarbamate carbamate (Tybamate) | |
| Albanus et al. | Antidote effect of sodium fluoride in organophosphorus anticholinesterase poisoning | |
| Rust Jr et al. | Plague toxin: its effect in vitro and in vivo | |
| Quilliam et al. | Some observations upon the pharmacological activity of di-isopropyl fluorophosphonate | |
| CA1209047A (en) | Therapeutic composition containing piracetam analog | |
| Besser et al. | High pancuronium sensitivity of axonal nicotinic‐acetylcholine receptors in humans during organophosphate intoxication | |
| EP1261346A1 (en) | Modulation of cardiovascular injury | |
| Calvey et al. | Kinetics of intravenous pyridostigmine in man. | |
| Lindquist | Determination of insulin and glucose post mortem | |
| RU2000779C1 (en) | Method of curing vitiligo | |
| SU665912A1 (en) | Ractivator of cholinesterase | |
| Dereymaeker et al. | Experimental epilepsy and blood–brain Barrier | |
| Faden et al. | Naloxone reversal of hypotension caused by spinal transection |